Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated IMRT with Temozolomide and GM-CSF for Glioblastoma
NCT02663440Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in glioblastoma multiforme (GBM), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
sargramostim
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02663440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663440.